BSX vs. SYK, BDX, DXCM, RMD, REGN, VRTX, MDT, CI, GSK, and ELV
Should you be buying Boston Scientific stock or one of its competitors? The main competitors of Boston Scientific include Stryker (SYK), Becton, Dickinson and Company (BDX), DexCom (DXCM), ResMed (RMD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Medtronic (MDT), The Cigna Group (CI), GSK (GSK), and Elevance Health (ELV). These companies are all part of the "medical" sector.
Boston Scientific (NYSE:BSX) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
Boston Scientific has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
Stryker has higher revenue and earnings than Boston Scientific. Stryker is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 77.1% of Stryker shares are owned by institutional investors. 0.5% of Boston Scientific shares are owned by insiders. Comparatively, 5.9% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Boston Scientific had 12 more articles in the media than Stryker. MarketBeat recorded 19 mentions for Boston Scientific and 7 mentions for Stryker. Stryker's average media sentiment score of 0.76 beat Boston Scientific's score of 0.59 indicating that Stryker is being referred to more favorably in the news media.
Boston Scientific received 108 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.33% of users gave Boston Scientific an outperform vote while only 64.51% of users gave Stryker an outperform vote.
Boston Scientific presently has a consensus target price of $75.32, indicating a potential upside of 0.90%. Stryker has a consensus target price of $365.94, indicating a potential upside of 9.34%. Given Stryker's higher probable upside, analysts plainly believe Stryker is more favorable than Boston Scientific.
Stryker has a net margin of 16.03% compared to Boston Scientific's net margin of 12.06%. Stryker's return on equity of 23.05% beat Boston Scientific's return on equity.
Summary
Stryker beats Boston Scientific on 10 of the 19 factors compared between the two stocks.
Get Boston Scientific News Delivered to You Automatically
Sign up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Boston Scientific Competitors List
Related Companies and Tools
